2020-12-172020-12-172019SANTOS, Danielle Borborema Tolentino dos; SANTOS, Jéssica Seibert dos. Desfechos clínicos de pacientes portadores de hepatite C crônica em um serviço de referência para tratamento das doenças do fígado. 2019. 71 f. Trabalho de Curso (Bacharelado em Medicina) - Faculdade de Medicina, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, 2019. Disponível em: http://hdl.handle.net/prefix/3242. Acesso em:.http://hdl.handle.net/prefix/3242Introduction: Hepatitis C virus infection is one of the leading causes of chronic liver disease worldwide, as approximately 85% of acute HCV infections progress to chronicity, with an insidious, slowly evolving progressive. Complications include cirrhosis and hepatocellular carcinoma. Thus, the goal of drug therapy is to cure HCV infection to prevent hepatic and extra-hepatic complications related to disease. Objective To describe the epidemiological profile of patients with chronic hepatitis C, besides investigating the main clinical outcomes and the results obtained after treatment. Methodology: It is an observational study of a historical cohort evaluating data from medical records. The sample was randomly selected and evaluated for inclusion and exclusion criteria. The data obtained were recorded in a database built in Microsoft Office Access and in the analysis were applied descriptive and inferential statistical methods. Results and Discussion: There were 108 patients evaluated, predominantly male (55.6%). Regarding age, the minimum and maximum were 35 and 85 years, respectively, with a mean of 60.7 years (SD + - 12.2 years). Of these, 57.4% had at least one comorbidity, with a higher prevalence of hepatic steatosis (27.8%). Among genotypes, genotype 1b (45.4%) was more frequent, followed by G3, G1a and G2 with prevalences of 28.7%, 20.4% and 3.7%, respectively. Of the total, 95.4% had their degree of fibrosis evaluated, finding a higher prevalence of grade 4 fibrosis (44.4%). In these patients, the complications were portal hypertension 47.9%, ascites (25%) and hepatic encephalopathy (6.25%). Of the cases, 75.9% were treated, in those patients the most used antiretroviral regimen was Sofosbuvir + Daclatasvir (30.5%) and the most frequent treatment time was 12 weeks (83%). Considering the response pattern presented, it can be seen that 76.8% did not have CRP at the end of treatment, but among the 19 cases recorded the SVR was 84.2%.Conclusion: The results obtained demonstrated similarities with the national and international literature regarding the epidemiological profile of chronic HCV patients. Regarding the treatment, in spite of the scarce data it was possible to demonstrate the high rate of SVR in the appropriately treated group and that the post-treatment follow-up with the CRP dosing.Acesso AbertoHepatite CEpidemiologiaDesfecho clínicoInfecçãoCNPQ::CIENCIAS DA SAUDE::MEDICINATrabalho de Curso - Graduação - Monografia